FY2025 · ended Dec 31, 2025 · Revenue $218.71M, +3024.4% YoY · Filed Feb 17, 2026
IDEAYA Biosciences, Inc. (IDYA) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $218.7 million and a net loss of $113.7 million. Free cash flow was -$73.5 million. As of Sep 30, 2026 it held $1.2 billion in cash and investments and $29.7 million in total debt.
Revenue (TTM)
$36.54M
-83.0% vs year-ago TTM
Net income (TTM)
$-420.01M
-161.3% vs year-ago TTM
Operating cash flow (TTM)
$-347.36M
-239.7% vs year-ago TTM
Free cash flow (TTM)
$-349.80M
-231.9% vs year-ago TTM
EPS (TTM)
$-4.51
-147.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
87.81M
+0.3% vs prior year
Net cash
$1.12B
as of Sep 30, 2026
Operating margin
-1267.3%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IDYA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1676725
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $218.7M | $7.0M | $23.4M | $50.9M | $27.9M |
| Operating income | -$159.3M | -$327.0M | -$134.4M | -$62.5M | -$50.3M |
| Net income | -$113.7M | -$274.5M | -$113.0M | -$58.7M | -$49.8M |
| Diluted EPS | -$1.28 | -$3.36 | -$1.96 | -$1.42 | — |
| Operating cash flow | -$71.1M | -$247.6M | -$115.2M | -$87.2M | -$55.8M |
| Free cash flow | -$73.5M | -$251.4M | -$117.6M | -$90.6M | -$58.4M |
| Total assets | $1.1B | $1.1B | $649.3M | $388.0M | $381.3M |
| Total liabilities | $86.4M | $64.9M | $28.2M | $38.5M | $79.8M |
| Stockholders' equity | $1.0B | $1.1B | $621.1M | $349.5M | $301.5M |
| Cash and investments | $1.0B | $1.1B | $632.6M | $373.1M | $368.1M |
| Total debt | $27.9M | $19.2M | $2.9M | $3.5M | $5.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 3, 2026 | Nov 3, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Shareholder vote results, Other events
|
Jun 23, 2026 | Jun 16, 2026 |
| 8-K |
Current report
Other events
|
Jun 10, 2026 | Jun 8, 2026 |
All 506 IDEAYA Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.